Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Summary

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP

Timeline

Start

2016-07

Primary completion

2023-04-12

Completion

2023-04-12

Drugs

Indications